Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue
نویسندگان
چکیده
منابع مشابه
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.
Individual cases of prolonged complete response (CR) of HER2-positive metastatic breast cancer (MBC) have been reported following treatment with trastuzumab/chemotherapy, but the frequency of durable remission is unknown [1, 2]. We carried out a retrospective study of long-term outcome of all patients with HER2-positive MBC treated in our institutions with chemotherapy and trastuzumab before Ma...
متن کاملPhospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer
Resistance to trastuzumab is frequently observed during the treatment of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancers. The aim of the present study was to determine if the phosphorylated proline-rich Akt substrate of 40 kDa (phospho-PRAS40Thr246), a novel biomarker for phosphoinositol-3 kinase (PI3K) pathway activation, could predict the response of HE...
متن کاملUse of Apoptotic Biomarkers to Predict Response to Radiotherapy in Breast Cancer Patients
Introduction: To enhance radiation therapy efficiency it is crucial to implement an individual-based treatment. The aim of present study was to identify the mechanism of intrinsic apoptosis pathway on radiosensitivity and normal tissue complications caused by the radiotherapy. Materials and Methods: radiation-induced apoptosis in periphera...
متن کاملNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer cell lines. We further assessed its effects with or without tra...
متن کاملMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2017
ISSN: 0923-7534
DOI: 10.1093/annonc/mdx532